Current prostate-specific antigen screening is not cost-effective from a public health perspective. A new algorithm using genetic testing and imaging has yet to be developed. See also pages 000-000.
from Cancer via ola Kala on Inoreader http://ift.tt/2ANQ3xP
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου